IgG-Paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier

Molecular Pharmaceutics

Volumn 5, Issue 6, 2008, Pages 1037-1043

  Boado, Ruben J ^a,b   Zhang, Yun ^a,b   Zhang, Yufeng ^a   Wang, Yuntao ^b   Pardridge, William M ^b  

^a ArmaGen Technologies Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Chemical nerve gas; Drug targeting; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHIMERIC ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G PARAOXONASE 1; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; ORGANOPHOSPHATE; PROTEIN A; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CELL STRAIN COS1; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME ENGINEERING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FLUOROMETRY; GENE; GENETIC TRANSFECTION; HEAVY CHAIN; HUMAN; HUMAN CELL; LETHALITY; LIGHT CHAIN; NUCLEOTIDE SEQUENCE; PLASMA; PRIORITY JOURNAL; PROTEIN PURIFICATION; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ARYLDIALKYLPHOSPHATASE; BLOOD-BRAIN BARRIER; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN G; MODELS, BIOLOGICAL; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, INSULIN; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 64649103437     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800113g     Document Type: Article

References (26)

1. Mackness, B.; Durrington, P.; Povey, A.; Thomson, S.; Dippnall, M.; Mackness, M.; Smith, T.; Cherry, N. Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 2003, 13, 81-88.
2. Russell, A. J.; Berberich, J. A.; Drevon, G. F.; Koepsel, R. R. Biomaterials for mediation of chemical and biological warfare agents. Annu. Rev. Biomed. Eng. 2003, 5, 1-27.
3. Yanagisawa, N.; Morita, H.; Nakajima, T. Sarin experiences in Japan: acute toxicity and long-term effects. J. Neurol. Sci. 2006, 249, 76-85.
4. Li, B.; Sedlacek, M.; Manoharan, I.; Boopathy, R.; Duysen, E. G.; Masson, P.; Lockridge, O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 2005, 70, 1673-1684.
5. Josse, D.; Lockridge, O.; Xie, W.; Bartels, C. F.; Schopfer, L. M.; Masson, P., The active site of human paraoxonase (PON1). J. Appl. Toxicol. 2001, 21 (Suppl. 1), S7-S11.
6. Yeung, D. T.; Josse, D.; Nicholson, J. D.; Khanal, A.; McAndrew, C. W.; Bahnson, B. J.; Lenz, D. E.; Cerasoli, D. M. Structure/ function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochim. Biophys. Acta 2004, 1702, 67-77.
7. Harel, M.; Aharoni, A.; Gaidukov, L.; Brumshtein, B.; Kherson- sky, O.; Meged, R.; Dvir, H.; Ravelli, R. B. G.; McCarthy, A.; Toker, L.; Silman, I.; Sussman, J. L.; Tawfik, D. S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 2004, 11, 412-119.
8. Rochu, D.; Chabriere, E.; Masson, P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophos- phorus poisoning. Toxicology 2007, 255, 47-59.
9. Gaidukov, L.; Tawfik, D. S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005, 44, 11843-11854.
10. Deakin, S.; Leviev, I.; Gomaraschi, M.; Calabresi, L.; Franceschini, G.; James, R. W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 2002, 277, 4301-4308.
11. Gillis, R. A.; Walton, D. P.; Quest, J. A.; Namath, I. J.; Hamosh, P.; Dretchen, K. L. Cardiorespiratory effects produced by activation of cholinergic muscarinic receptors on the ventral surface of the medulla. J. Pharmacol. Exp. Ther. 1988, 247, 765-773.
12. Choi, E. K.; Park, D.; Yon, J. M.; Hur, G. H.; Ha, Y. C.; Che, J. H.; Kim, J.; Shin, S.; Jang, J. Y.; Hwang, S. Y.; Seong, Y. H.; Kim, D. J.; Kim, J. C.; Kim, Y. B. Protection by sustained release of physostigmine and procyclidine of soman poisoning in rats. Eur. J. Pharmacol. 2004, 505, 83-91.
13. Bird, S. B.; Gaspari, R. J.; Dickson, E. W. Early death due to severe organophosphate poisoning is a centrally mediated process. Acad. Emerg. Med. 2003, 10, 295-298.
14. Pardridge, W. M. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconiugate Chem. 2008, 19, 1327-1338.
15. Boado, R. J.; Zhang, Y.; Zhang, Y.; Pardridge, W. M. Humaniza- tion of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 2007, 96, 381-391.
16. Boado, R. J.; Zhang, Y.; Zhang, Y.; Pardridge, W. M. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng. 2007, 97, 1376-1386.
17. Boado, R. J.; Zhang, Y.; Zhang, Y.; Xia, C. F.; Pardridge, W. M. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconiugate Chem. 2007, 18, 447-455.
18. Boado, R. J.; Zhang, Y.; Zhang, Y.; Xia, C. F.; Pardridge, W. M. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotech- nol. Bioeng. 2008, 99, 475-484.
19. Draganov, D. I.; Teiber, J. F.; Speelman, A.; Osawa, Y.; Sunahara, R.; La Du, B. N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 2005, 46, 1239-1247.
20. Coloma, M. J.; Lee, H. J.; Kurihara, A.; Landaw, E. M.; Boado, R. J.; Morrison, S. L.; Pardridge, W. M. Transport across the primate blood- brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 2000, 17, 266-274.
21. Soukharev, S.; Hammond, D. J. A fluorogenic substrate for detection of organophosphatase activity. Anal. Biochem. 2004, 527, 140-148.
22. Lenz, D. E.; Yeung, D.; Smith, J. R.; Sweeney, R. E.; Lumley, L. A.; Cerasoli, D. M. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 2007, 233, 31-39.
23. Kujiraoka, T.; Oka, T.; Ishihara, M.; Egashira, T.; Fujioka, T.; Saito, E.; Saito, S.; Miller, N. E.; Hattori, H. A sandwich enzyme- linked immunosorbent assay for human serum paraoxonase concentration. J. Livid. Res. 2000, 41, 1358-1363.
24. Paragh, G.; Seres, I.; Harangi, M.; Erdei, A.; Audikovszky, M.; Debreczeni, L.; Kovácsay, A.; Illyes, L.; Pados, G. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. Br. J. Clin. Pharmacol. 2006, 61, 694-701.
25. Draganov, D. I.; La Du, B. N. Pharmacogenetics ofparaoxonases: a brief review. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369, 78-88.
26. Durrington, P. N.; Mackness, B.; Mackness, M. I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 473-480.